Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study
J. Clin. Oncol 2022 Sep 07;[EPub Ahead of Print], O Adotévi, D Vernerey, P Jacoulet, A Meurisse, C Laheurte, H Almotlak, M Jacquin, V Kaulek, L Boullerot, M Malfroy, E Orillard, G Eberst, A Lagrange, L Favier, M Gainet-Brun, L Doucet, L Teixeira, Z Ghrieb, AL Clairet, Y Guillaume, M Kroemer, D Hocquet, M Moltenis, S Limat, E Quoix, C Mascaux, D Debieuvre, C Fagnoni-Legat, C Borg, V WesteelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.